Literature DB >> 15729565

Monitoring of liver metastases after stereotactic radiotherapy using low-MI contrast-enhanced ultrasound--initial results.

M Krix1, C Plathow, M Essig, K Herfarth, J Debus, H-U Kauczor, S Delorme.   

Abstract

The purpose of this study was to monitor liver metastases after radiotherapy using contrast-enhanced ultrasound (CEUS). In 15 patients, follow-up examinations after stereotactic, single-dose radiotherapy were performed using CEUS (low mechanical index (MI), 2.4-ml SonoVue) and computed tomography (CT). Besides tumor size, the enhancement of the liver and the metastases was assessed at the arterial, portal venous, and delayed phases. The sizes of the tumor and of a perifocal liver reaction after radiotherapy measured with CEUS significantly correlated with those measured at CT (r=0.93, p<0.001). CEUS found a significant reduction of the arterial vascularization in treated tumors (p<0.05). In the arterial phase, the perifocal liver tissue was hypervascularized compared to the treated tumor (p<0.001); in the late phase, it was less enhanced than the liver (p<0.001) and more than the tumor (p<0.01). The perifocal liver reaction was also seen in CT, but with a variable enhancement at the arterial (50% hyperdense compared to normal liver tissue), venous, or delayed phase (each with 70% hyperdense reactions). CEUS allows for the assessment of tumor and liver perfusion, in addition to morphological tumor examination, which was comparable with CT. Thus, changes of tumor perfusion, which may indicate tumor response, as well as the perifocal liver reaction after radiotherapy, which must be differentiated from perifocal tumor growth, can be sensitively visualized using CEUS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15729565     DOI: 10.1007/s00330-004-2620-x

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  28 in total

1.  Hepatic clearance of Sonazoid perfluorobutane microbubbles by Kupffer cells does not reduce the ability of liver to phagocytose or degrade albumin microspheres.

Authors:  Grete Mørk Kindberg; Helge Tolleshaug; Norbert Roos; Tore Skotland
Journal:  Cell Tissue Res       Date:  2003-02-27       Impact factor: 5.249

2.  Quantitative dynamic contrast-enhanced sonography of hepatic tumors.

Authors:  Detlef Klein; Manfred Jenett; Heinz-Jochen Gassel; Jörn Sandstede; Dietbert Hahn
Journal:  Eur Radiol       Date:  2004-04-24       Impact factor: 5.315

3.  Evaluation of hepatocellular carcinoma using SonoVue, a second generation ultrasound contrast agent: correlation with cellular differentiation.

Authors:  Carlos Nicolau; Violeta Catalá; Ramón Vilana; Rosa Gilabert; Luis Bianchi; Manel Solé; Mario Pagés; Concepció Brú
Journal:  Eur Radiol       Date:  2004-03-09       Impact factor: 5.315

4.  Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion.

Authors:  K Wei; A R Jayaweera; S Firoozan; A Linka; D M Skyba; S Kaul
Journal:  Circulation       Date:  1998-02-10       Impact factor: 29.690

Review 5.  Liver metastases: interventional therapeutic techniques and results, state of the art.

Authors:  T J Vogl; P K Müller; M G Mack; R Straub; K Engelmann; P Neuhaus
Journal:  Eur Radiol       Date:  1999       Impact factor: 5.315

6.  CT evaluation of hepatic injury following proton beam irradiation: appearance, enhancement, and 3D size reduction pattern.

Authors:  T Ahmadi; Y Itai; H Onaya; H Yoshioka; T Okumura; Y Akine
Journal:  J Comput Assist Tomogr       Date:  1999 Sep-Oct       Impact factor: 1.826

7.  Detection of liver metastases by pulse inversion harmonic imaging during Levovist late phase: comparison with conventional ultrasound and helical CT in 160 patients.

Authors:  Emilio Quaia; Michele Bertolotto; Balázs Forgács; Alessandra Rimondini; Martina Locatelli; Roberto Pozzi Mucelli
Journal:  Eur Radiol       Date:  2002-09-26       Impact factor: 5.315

Review 8.  Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future.

Authors:  W Y Lau; Thomas W T Leung; Simon C H Yu; Stephen K W Ho
Journal:  Ann Surg       Date:  2003-02       Impact factor: 12.969

9.  Spectroscopic and perfusion magnetic resonance imaging predictors of progression in pediatric brain tumors.

Authors:  A Aria Tzika; Loukas G Astrakas; Maria K Zarifi; David Zurakowski; Tina Young Poussaint; Liliana Goumnerova; Nancy J Tarbell; Peter McL Black
Journal:  Cancer       Date:  2004-03-15       Impact factor: 6.860

10.  The triple-phase CT image appearance of post-irradiated livers.

Authors:  S Y Chiou; R C Lee; K H Chi; J Chia-Hsien Cheng; J H Chiang; C Y Chang
Journal:  Acta Radiol       Date:  2001-09       Impact factor: 1.701

View more
  14 in total

Review 1.  [Possible target specific molecular imaging with ultrasound contrast agents].

Authors:  M Mäurer; R Linker; M Reinhardt; P Hauff
Journal:  Radiologe       Date:  2005-06       Impact factor: 0.635

Review 2.  Microbubble ultrasound contrast agents: an update.

Authors:  Emilio Quaia
Journal:  Eur Radiol       Date:  2007-03-10       Impact factor: 5.315

3.  Comparison of contrast-enhanced ultrasonography versus baseline ultrasound and contrast-enhanced computed tomography in metastatic disease of the liver: diagnostic performance and confidence.

Authors:  Emilio Quaia; Mirko D'Onofrio; Alessandro Palumbo; Stefania Rossi; Stefano Bruni; Maria Cova
Journal:  Eur Radiol       Date:  2006-03-22       Impact factor: 5.315

4.  Undetectable late hepatic sequelae after hypofractionated stereotactic radiotherapy for liver tumors.

Authors:  Peter Gunvén; Eduard Jonas; Henric Blomgren; Eva Rutkowska; Kristin Karlsson; Ingmar Lax; Seymour Levitt
Journal:  Med Oncol       Date:  2010-05-19       Impact factor: 3.064

5.  Molecular and clinical aspects of targeting the VEGF pathway in tumors.

Authors:  Grzegorz Korpanty; Laura A Sullivan; Elizabeth Smyth; Desmond N Carney; Rolf A Brekken
Journal:  J Oncol       Date:  2010-06-10       Impact factor: 4.375

6.  Contrast-enhanced ultrasound after devascularisation of neuroendocrine liver metastases: functional and morphological evaluation.

Authors:  Aymeric Guibal; Thibaud Lefort; Laurence Chardon; Noura Benslama; Sébastien Mulé; Franck Pilleul; Catherine Lombard-Bohas; Lori Bridal; Jean Alain Chayvialle; Olivier Lucidarme; Alban Denys; Thomas Walter
Journal:  Eur Radiol       Date:  2012-09-22       Impact factor: 5.315

7.  Semi-automated measurement of hyperdense, hypodense and heterogeneous hepatic metastasis on standard MDCT slices. Comparison of semi-automated and manual measurement of RECIST and WHO criteria.

Authors:  Sebastian Keil; Florian F Behrendt; Sven Stanzel; Michael Sühling; Alexander Koch; Jhenee Bubenzer; Georg Mühlenbruch; Andreas H Mahnken; Rolf W Günther; Marco Das
Journal:  Eur Radiol       Date:  2008-06-04       Impact factor: 5.315

8.  Contrast enhancement ultrasound application in focal liver lesions characterization: a retrospective study about guidelines application (SOCEUS-CEUS survey).

Authors:  Mirko D'Onofrio; Laura Romanini; Carla Serra; Fabrizio Magnolfi; Michele Bertolotto; Emilio Quaia; Gino Puntel; Alessandro Colleoni; Erica Fiorini; Cristina Cenci; Elena Santi; Valentina Ciaravino; Francesco Laffranchi; Orlando Catalano; Vito Cantisani; Fabrizio Calliada; Lorenzo Derchi
Journal:  J Ultrasound       Date:  2015-11-02

9.  Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: a prospective controlled two-center study.

Authors:  E M Jung; D A Clevert; A G Schreyer; S Schmitt; J Rennert; R Kubale; S Feuerbach; F Jung
Journal:  World J Gastroenterol       Date:  2007-12-21       Impact factor: 5.742

10.  Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma?

Authors:  R Vilana; L Bianchi; M Varela; C Nicolau; M Sánchez; C Ayuso; M García; M Sala; J M Llovet; J Bruix; C Bru
Journal:  Eur Radiol       Date:  2006-05-18       Impact factor: 7.034

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.